Stockreport

JPM26: Vor Bio narrows focus to two-indication strategy [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF therapy to telitacicept, a dual BAFF/APRIL in-licensed from China-based Remegen in mid-2025. CEO Jean-Paul Kress, MD, emphasised that telitacicept has been clinically va [Read more]